Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PNETs) are classified based on their histologic differentiation and proliferative indices, which have been used extensively to determine prognosis. Advances in next-generation sequencing and other high-throughput techniques have allowed researchers to objectively ex...
Main Authors: | Praveen Dilip Chatani, Sunita Kishore Agarwal, Samira Mercedes Sadowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.575620/full |
Similar Items
-
Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
by: Lola-Jade Palmieri, et al.
Published: (2020-06-01) -
CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms
by: Chen X, et al.
Published: (2020-06-01) -
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
by: He-Li Gao, et al.
Published: (2020-10-01) -
Imaging presentation of pancreatic neuroendocrine neoplasms
by: Valentina Ciaravino, et al.
Published: (2018-10-01) -
Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology
by: Xu Han, et al.
Published: (2018-02-01)